Rockland L, Cooper T, Schwartz F, Weber D, Sullivan T
Adult Outpatient Department, New York Hospital, Westchester Division, White Plains 10605.
Can J Psychiatry. 1990 Oct;35(7):604-7. doi: 10.1177/070674379003500708.
This study investigated the effects of trihexyphenidyl on chlorpromazine (CPZ) plasma levels and clinical state in 20 relatively young schizophrenic patients diagnosed using the DSM-III. Spontaneous changes in CPZ plasma levels over time were also examined. Trihexyphenidyl significantly increased CPZ plasma levels (average 41%) but did not produce clinical change. The trihexphenidyl-induced increase in CPZ plasma levels was independent of CPZ oral dosage and of CPZ plasma levels. Chlorpromazine plasma levels decreased non significantly (about 13%) over the four weeks following steady state, but there was marked inter-subject variability, and CPZ levels rose in some subjects. Although identical CPZ doses produced widely variable plasma levels, CPZ plasma levels correlated significantly with oral dose. The views that antiparkinsonian drugs interfere with neuroleptic efficacy, and do so by lowering neuroleptic plasma levels, are questioned.
本研究调查了苯海索对20例根据《精神疾病诊断与统计手册》第三版(DSM-III)诊断的相对年轻的精神分裂症患者氯丙嗪(CPZ)血浆水平和临床状态的影响。同时也研究了CPZ血浆水平随时间的自发变化。苯海索显著提高了CPZ血浆水平(平均41%),但未产生临床变化。苯海索引起的CPZ血浆水平升高与CPZ口服剂量及CPZ血浆水平无关。在达到稳态后的四周内,氯丙嗪血浆水平无显著下降(约13%),但个体间存在明显差异,部分受试者的CPZ水平有所上升。尽管相同剂量的CPZ产生的血浆水平差异很大,但CPZ血浆水平与口服剂量显著相关。抗帕金森病药物会干扰抗精神病药物疗效并通过降低抗精神病药物血浆水平来实现这一观点受到质疑。